KPC Pharmaceuticals,Inc

Equities

600422

CNE0000015P8

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
22.53 CNY +2.41% Intraday chart for KPC Pharmaceuticals,Inc +5.33% +8.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kunyao Group Receives Clinical Trial Approval for FMF Drug MT
KPC Pharmaceuticals,Inc Proposes Cash Dividend CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
KPC Pharmaceuticals,Inc Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
KPC Pharmaceuticals’ Antimalarial Drug Passes WHO Prequalification MT
KPC Pharmaceuticals' Attributable Profit Rises 3.1%; Shares Slip 4% MT
KPC Pharmaceuticals,Inc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
KPC Pharmaceuticals' Q1 Net Profit Jumps; Shares Rise 7% MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
KPC Pharma’s Shingles Drug Added to China’s Medical Insurance Catalog MT
KPC Pharma to Hold Phase II Clinical Trial of Stroke Drug MT
China Resources Pharmaceutical Completes Transfer of KPC Pharmaceutical Shares to Unit MT
KPC Pharmaceuticals CFO Steps Down MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. completed the acquisition of a 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited. CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
KPC Pharmaceuticals Unit Receives Marketing Authorization of Angong Niuhuang Pills; Shares Jump 7% MT
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chinese Shares Rebound; KPC Pharma Rallies 10% on CR Sanjiu’s $431 Million Stake Purchase MT
CR Sanjiu Medical & Pharma to Buy 28% Stake in KPC Pharma For $430 Million MT
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. from Hofon Pharmaceuticals Co.,Ltd. and Holley Group Company Limited for CNY 2.9 billion. CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
KPC Pharmaceuticals, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Kpc Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart KPC Pharmaceuticals,Inc
More charts
KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.53 CNY
Average target price
25.01 CNY
Spread / Average Target
+11.01%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600422 Stock
  4. News KPC Pharmaceuticals,Inc
  5. KPC Pharmaceuticals’ Antimalarial Drug Passes WHO Prequalification